- Real-world data shows a 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating with inFoods® IBS.
- Biomerica (BMRA, Financial) unveils a HIPAA-compliant real-time feedback system to enhance IBS treatment.
- IBS impacts 10-15% of U.S. adults, highlighting a significant market for non-drug therapies.
Biomerica, Inc. (BMRA) has released compelling real-world data demonstrating the effectiveness of its inFoods® IBS diagnostic-guided therapy. Over an 8-week period, more than 360 patients reported an average reduction of 48.5% in gastrointestinal pain and 49.8% in bloating. This aligns with previous clinical trial results and underscores the potential of this non-drug treatment approach in reducing IBS symptoms.
The company has also launched a new HIPAA-compliant real-time patient feedback system that enables physicians to monitor symptoms and tailor treatment plans dynamically. This innovative system allows for continuous tracking of patient-reported outcomes, such as abdominal discomfort and overall well-being, significantly enhancing clinical decision-making.
Biomerica’s inFoods® IBS approach shifts the paradigm from traditional IBS treatments that often rely on medications, targeting instead specific food triggers identified through their diagnostic system. This personalized method offers a non-pharmaceutical solution, reducing dependence on medication, which can have adverse side effects.
The substantial market potential for Biomerica's inFoods® IBS product is highlighted by the fact that IBS affects an estimated 10-15% of adults in the U.S. This solution offers significant benefits, not just in symptom management but also in improving the overall quality of life for patients.
Furthermore, a peer-reviewed study, published in Gastroenterology, confirmed the efficacy of the inFoods® IBS approach, showing significantly more abdominal pain relief compared to placebo (59.6% vs. 42.1%, p-value=0.02).
Biomerica continues to position itself as a leader in the medical device sector, with a focus on innovative diagnostic and therapeutic products that enhance healthcare outcomes while potentially reducing overall costs.
